The Wall Street Journal: Pfizer working on freeze-dried version of COVID-19 vaccine that doesn’t need ultracold storage


Pfizer Inc.

 and partner BioNTech SE

 plan to begin soon testing a freeze-dried version of its COVID-19 vaccine, which if proven to work safely could ease storage and handling of the shots in rural U.S. areas and low-income countries.

In April, Pfizer is set to start a clinical trial evaluating a so-called lyophilized formulation in adults 18 to 55 years old in the U.S., according to a government database,, and confirmed by the company.

The 1,100-subject study would last about two months, with researchers seeking to determine whether the lyophilized version is as safe and effective as the version authorized by regulators beginning late last year. Researchers would administer to subjects either the lyophilized version or the current formulation.

If successful, the new formulation could be ready for use by early next year, Pfizer said on an earnings call last month.

Lyophilized vaccines offer advantages to frozen or liquid vaccines because they only need standard refrigeration. That would help with storage and handling and expand access in rural areas and low-income countries that lack specialized equipment. Examples of vaccines that can be lyophilized include shots for preventing shingles or rotavirus.

An expanded version of this report appears on

Also popular on

COVID-19 vaccination cards are the only proof of shots, soon an essential.

Democrats look at lowering Medicare eligibility age in healthcare package.

What’s Worth Streaming: Here’s everything coming to Amazon Prime Video in April 2021

Previous article

: JPMorgan’s Jamie Dimon says voting ‘must be accessible and equitable’ in wake of Georgia law

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News